Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome

Luca Castagna1 · Thomas Pagliardini2 · Stefania Bramanti1 · Jean Marc Schiano de Colella2 · Catalina Montes de Oca2 · Reda Bouabdallah2 · Jacopo Mariotti1 · Sabine Fürst2 · Angela Granata2 · Chiara De Philipps1 · Samia Harbi2 · Barbara Sarina1 · Faezeh Legrand2 · Valerio Maisano2 · Pierre Jean Weiller2 · Christian Chabannon3 · Carmelo Carlo-Stella1,4 · Armando Santoro1,4 · Didier Blaise2 · Raynier Devillier2

Received: 15 June 2020 / Revised: 8 September 2020 / Accepted: 2 November 2020 / Published online: 15 November 2020
© The Author(s), under exclusive licence to Springer Nature Limited 2020

Abstract
We report the outcome of 68 patients with advanced peripheral T-cell lymphoma receiving transplantation from haploidentical or from conventional donors. The 4-year OS, PFS, 2-year cumulative incidence of relapse and 2-year GRFS was 75%, 70%, 21%, and 51%, respectively. Survival was not affected by donor type. The 2-year NRM was 9%, lower after related or haploidentical donor (21% vs 0% vs 7%; \( p = 0.06 \)). Grade 2–4 aGVHD cumulative incidence was significantly different after transplantation from haploidentical vs matched sibling vs unrelated donor, and (24% vs 35% vs 58%, \( p = 0.024 \)). The familial donor cohort was compared to the unrelated cohort. Familial donor induced less grade 2–4 aGVHD, with a trend to less grade 3–4 aGVHD or moderate-severe cGVHD. The OS and PFS were not different, while the relapse risk and NRM were reduced. Allo-SCT is highly effective in T-cell lymphoma, with low NRM and low relapse rate. The incidence of aGVHD was lower after haploidentical transplantation. Related donor may challenge unrelated transplant reducing the risk of relapse and NRM.

Background
Peripheral T-cell non-Hodgkin lymphomas (PTCL) account for ~10% of aggressive non-Hodgkin lymphoma cases [1]. The prognosis of PTCL is unfavorable, with the remarkable exception of ALK-positive cases. Currently, 5-year disease-free survival for PTCL after conventional first-line chemotherapy is ~30% [2]. Although no prospective randomized trial was performed, prospective studies suggest, when feasible, that the use of high-dose chemotherapy (HDC) with autologous stem cell transplantation as consolidation therapy in first-line therapy can improve the survival rate to 50–60% [3, 4].

In patients with relapse or refractory (R/R) PTCL, the outcome is dismal (median overall survival (OS), 5 months) regardless of the selected salvage regimen, as reported by the MD Anderson [5, 6] and the Swedish Lymphoma Registry (median OS, 6 months) [7]. OS has not been influenced by recently introduced drugs, such as BV, romidepsine, belinostat, and palatrexate [8].

In the setting of R/R PTCL, allogeneic stem cell transplantation (allo-SCT) remains the only treatment that can significantly lead to long term DFS, as reported in several retrospective analyses [9–12]. Recently, Loirat et al. reported the results from an intent-to-treat analysis of upfront allo-SCT for PTCL showing promising outcome (5-year OS 72%) when allo-SCT was actually performed [13].

The development of T-cell replete allo-SCT from haploidentical donors (haplo-SCT) using post-transplantation...
cyclophosphamide (PT-Cy) as part of GVHD prophylaxis has allowed a wide extension of transplantation possibilities to treat hematological malignancies. In Europe and the USA, this platform [14] is the most popular, leading to low incidences of GVHD and NRM. In the specific context of lymphoma patients (HL and NHL), several papers [15–24] reported promising outcome after PT-Cy Haplo-SCT, confirming that this procedure is a valuable alternative to matched sibling (MSD) or unrelated (URD) donor allo-SCT. However, few patients in these cohorts were affected by PTCL.

Here, we analyzed the outcome of Haplo-SCT in patients affected by R/R PTCL and we compared them with those obtained in patients receiving allo-SCT from a MSD or URD during the same period of time.

**Patients and methods**

We identified 68 patients with PTCL between 2010 and 2019. All histological diagnoses of PTCL subtypes according to the World Health Organization criteria are represented. The retrospective collection and analysis of patient data from internal transplantation database were approved by the ethical committee of the institutional review board (NHLT-Haplo-IPC 2020–033). All patients signed informed consent.

Patients were candidates for allo-SCT when they met the following criteria: relapse after HDC; relapse or refractory after conventional chemotherapies; lack of mobilization of autologous stem cells in first-line remission; high risk of relapse based on clinical characteristics. In the absence of a MSD or URD, patients were candidates for transplantation from a haploidentical donor (HAPLOD). General eligibility criteria to proceed to allo-SCT were absence of uncontrolled infections, low Karnofsky performance status (<60%), absence of severe organ dysfunction, including a left ventricular ejection fraction <40%, diffusion lung capacity for carbon monoxide or Forced expiratory volume < 50%, or creatinine clearance <50 mL/min. The hematopoietic stem cell comorbidity index (HCT-CI) was calculated for each patient [25].

Conditioning regimen for haplo-SCT were either non-myeloablative (NMAC)—associating fludarabine 30 mg/m² from day −6 to day −2, cyclophosphamide (Cy) 14.5 mg/kg on days −5 and −6) and 2 Gy total body irradiation on day −1 - or reduced intensity (RIC) consisting of thiotepa 5 mg/kg on day-6, fludarabine 30 mg/m² from day-5 to day-2, and iv eusulfan 3.2 mg/kg on day-4 and day-3) regimens. GVHD prophylaxis was based on PT-Cy 50 mg/kg on day +3 and day +4, tacrolimus or cyclosporine A (CsA) and mycophenolate mofetil from day +5, as previously described.

For allo-SCT from MSD and URD, two RIC regimens were used: fludarabine 30 mg/m² (day −6 to day −2), iv busulfan 3.2 mg/kg (day −5 to day −4) and ATG 2.5 mg/kg (day −1). thiotepa 6 mg/kg ×2, Cy 30 mg/kg (day −4 to day +3), fludarabine 30 mg/m² (day −4 to day −3), and ATG (2.5 mg/kg/day on day −3 and −2). Post-transplant GVHD prophylaxis consisted of CsA from d −1. Four patients receiving MSD did not receive ATG. Four patients received NMAC because of high HCT-CI and/or relapse after high-dose chemotherapy.

Acute GVHD was graded according to the Keystone criteria [26], and chronic GVHD was graded following NIH criteria [27].

**Engraftment**

Neutrophil recovery was defined as an absolute neutrophil count (ANC) > 0.5 × 10⁹/L for three consecutive days without growth factor support. Platelet recovery was defined as a platelet count of 20 × 10⁹/L, without transfusions in the previous 7 days.

**Statistical considerations**

Outcomes were calculated from the date of allo-SCT. The Kaplan–Meier method was used for OS and progression free survival (PFS) analyses and univariate comparisons were made using log-rank test. PFS is defined as the time from starting allo-SCT to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first. OS is defined as the time from starting the date of allo-SCT to death due to any cause. Patients were censored at last contact in absence of relevant events. We calculated GVHD and relapse free survival (GRFS) using a composite end point considering relapse, death, grade 3–4 acute GVHD, and moderate to severe chronic GVHD as relevant events. The cumulative incidences of GVHD, NRM and disease progression (or relapse) were computed using the Prentice method taking into account the presence of competing risk (death from any cause for GVHD while NRM and relapse were considered as mutually competing events). Univariate comparisons were performed using Grey test. Cox regression was performed to adjust the impact of donor type on outcome by including age (continuous variable) and disease status at the time of allo-SCT (CR vs. PR or less) in the model. In complement of per donor-group analysis, using a practical approach, we performed a second analysis of these data comparing familial (MSD and haploidentical donor = RD) and URD.

All statistical analyses were performed using R-project software (https://www.r-project.org/).
A total of 68 PTCL patients were included in this study. Patient characteristics are reported in Table 1. Twenty-nine patients received transplantation from HAPLOD (43%), 20 (29%) from MSD, and 19 from URD (28%). At the time of allo-SCT, 50 (74%) and 14 (21%) patients were in complete (CR) and partial remission (PR), respectively. The median follow-up was 55 months (range 12–116).

### Results

The median time to obtain unsupported ANC and platelet count was 18 days (range 8–57), and 15 days (range 8–257), respectively. Sixty-one patients (90%) were evaluable for chimerism and 4 (7%, 3 after allo-SCT from MDS and 1 after haplo-SCT) obtained mixed chimerism and 57 (93%) full donor chimerism. Chimerism was not obtained in seven patients because of early death [4] and unavailability of results [3].

### Engraftment and chimerism

The median time to obtain unsupported ANC and platelet count was 18 days (range 8–57), and 15 days (range 8–257), respectively. Sixty-one patients (90%) were evaluable for chimerism and 4 (7%, 3 after allo-SCT from MDS and 1 after haplo-SCT) obtained mixed chimerism and 57 (93%) full donor chimerism. Chimerism was not obtained in seven patients because of early death [4] and unavailability of results [3].
Acute and chronic GVHD

For the whole population, the cumulative incidence of grade 2–4 and grade 3–4 aGVHD was 37% (95CI: 27–50) and 10% (95CI: 5–21), respectively. The 2-year cumulative incidence of moderate/severe cGVHD was 15% (95CI: 8–26). The cumulative incidence of grade 2–4 aGVHD was significantly lower after haplo-SCT compared to MSD and URD allo-SCT (Haplo 24% vs MSD 35% vs URD 58%, p = 0.024, Fig. 1A). Although not significant, we observed a lower incidence of grade 3–4 aGVHD in the HAPLOD group (3%), while corresponding value for MSD and URD groups were 15% and 16%, respectively (global p = 0.17) (Table 2). The cumulative incidence of moderate/severe cGVHD at 2 years was 10%, 10%, and 26% in the HAPLOD, MSD, and URD groups, respectively (p = 0.238, URD vs. other, p = 0.09, Fig. 1B).

In an exploratory multivariate analysis, allo-SCT from URD (but not from MSD) significantly enhanced the risk to develop grade 2–4 compared to HAPLOD (HR 3.86 95CI 1.47–10.14, p = 0.006 (Table A, supplementary file). Due to low number of events, MV was not performed for grade 3–4 acute GVHD and chronic GVHD.

Survival, relapse, NRM, GRFS

The 4-year OS and PFS (Fig. 2), GRFS and CIR and NRM for the entire cohort was 75% (95CI: 65–86), 70% (95CI: 60–82), 51% (95CI: 41–65), 21% (95CI: 13–33), and 9% (95CI: 4–19), respectively. These outcomes were analyzed by donor type (HAPLOD vs MSD vs URD): 4-year OS was 76% vs 80% vs 68% (p = 0.654); 4-year PFS were 72% vs 69% vs 68% (p = 0.9); CIR was 21% vs 31% vs 11% (p = 0.3), respectively. The 2-year GRFS was 59% vs 50% vs 42% (p = 0.5). The 4-year NRM was 7, 0 and 21% (global p = 0.067, Fig. 3). Exploratory multivariate analyses for OS, PFS, and GRFS did not show any difference between donor groups (Table B, supplementary file). Due to low number of events, MV was not performed for NRM and relapse.

Main events and outcome endpoints were analyzed within two donor groups (RD vs URD). Main patient characteristics are presented in supplemental file (Table C) and the two groups showed similar characteristics, except for intensity of conditioning regimen, which was higher in URD group. In the univariate analysis, OS, PFS and GRFS were not different, but the CI of grade 2–4 and the 4-year NRM were significantly higher in the URD group (58 vs 29%, p = 0.008 and 21 vs 4%, p = 0.03, respectively) (Fig. 1A, B supplementary file).

Discussion

This retrospective analysis suggests that allo-SCT allows for long-term disease control in poor prognosis PTCL, using any donor type. Indeed, 4-year OS, PFS, CIR, NRM, and GRFS for the entire cohort were 75, 70, 21, 9, and 51%.

The patient population included in this study was obviously selected as 95% of them were in CR or PR before the transplantation. On the other hand, we dealt with heavily pre-treated patients (median number of previous chemotherapy lines was 3) and almost 30% of patients relapsed after high-dose chemotherapy. Therefore, this study cannot answer whether allo-SCT should be considered as first line consolidation treatment; however, it sheds some light on the real-life outcome of patients affected by R/R PTCL who received allo-SCT from different donors in a recent period of time. The median age (56 years) of our patients, slightly higher than reported in the literature, and HCT-CI score ≥3 in 56% of patients outline that our population is representative of real-life medical practices.

A peculiar characteristic of this study was the high number of patients allografted from HAPLOD (43%). In the
literature, very few haplo-SCT have been reported in T-cell lymphoma. The CIBMTR included, in two studies [18, 19], 185 and 180 lymphoma patients received haplo-SCT and of these, 21 were T-cell lymphomas. In the Kanate’s study [18], comparing haplo-SCT to URD-SCT, PFS, and OS were not significant affected by donor types, even if a trend toward a better outcome was observed for patients receiving URD without ATG compared to HAPLOD (3-y PFS 51 vs 32%, OS 58 vs 36%). The EBMT reported on 59 lymphoma patients treated with haplo-SCT with PT-Cy. In this paper, the number of T-cell lymphoma patients was unknown, but the relapse incidence in T-cell lymphoma was lower than diffuse large B cell lymphoma and higher than follicular lymphoma, with direct consequences on the PFS [20].

In this study, 4-year PFS and OS, and 2-year CIR were similar for all donor types, while the NRM was lower after haplo-SCT as compared to transplantation from URD. It is interesting to note that, in this series, the disease status before allo-SCT did not have any impact on the outcomes, probably due to an effective graft versus lymphoma effect, similarly to what was reported by Le Gouill et al. [28].

Table 2 Univariate analysis.

|                        | HAPLOD (n = 29) | MSD (n = 20) | URD (n = 19) | p value |
|------------------------|----------------|--------------|--------------|---------|
| Acute GVHD             |                |              |              |         |
| Grade 2–4              | 24% (13–46)    | 35% (19–64)  | 58% (39–85)  | 0.024   |
| Grade 3–4              | 3% (1–24)      | 15% (5–43)   | 16% (6–45)   | 0.169   |
| Chronic GVHD           |                |              |              |         |
| Overall                | 14% (6–34)     | 15% (5–43)   | 32% (16–61)  | 0.284   |
| Moderate + severe      | 10% (4–30)     | 10% (3–37)   | 26% (12–56)  | 0.238   |
| NRM@4y                 | 7% (2–26)      | 0% NA        | 21% (9–50)   | 0.067   |
| CIR@4y                 | 21% (10–42)    | 31% (16–60)  | 11% (3–39)   | 0.369   |
| PFS@4y                 | 72% (58–91)    | 69% (51–93)  | 68% (50–93)  | 0.988   |
| OS@4y                  | 76% (62–93)    | 80% (64–100) | 68% (50–93)  | 0.654   |
| GRFS@2y                | 59% (43–80)    | 50% (32–78)  | 42% (25–71)  | 0.547   |

HAPLOD haploidentical donor, MSD matched sibling donor, URD unrelated donor, NRM nonrelapse mortality, OS overall survival, PFS progression free survival, CIR cumulative incidence of relapse, GRFS graft-relapse free survival

Fig. 2 Survival for the entire population. a Progression free survival; b overall survival.

Fig. 3 Non-relapse mortality by donor type. Cumulative incidences of NRM by donor type.
The CI of grade 2–4 aGVHD, but not 3–4, was significantly lower with HAPLOD than MSD and URD (35% vs 24% and 58%, \( p = 0.02 \)). This was slightly different from the CIBMTR studies, in which the authors found a statistical difference only for grade 3–4 aGVHD favoring HAPLOD as compared to URD [18], while no difference was apparent when compared to MSD [19]. On the other hand, we confirm the significantly lower incidence of cGVHD after haplo-SCT, similarly to CIBMTR studies.

In recent years, the mortality rate after allo-SCT has been lowered for several reasons [29]. Our cohort of patients was allografted in the last ten years, and the 2-year NRM was less than 10%. There was a trend to higher 4-year NRM for patients receiving allo-SCT from URD compared to MSD or HAPLOD (21% vs 0% vs 7%, \( p = 0.06 \)). In the CIBMTR studies, the NRM after haplo-SCT was similar to that observed with MDS and URD with or without ATG [18, 19]. Similarly, the risk of grade 2–4 was higher with URD than with RD. However, no difference in term of OS, PFS and relapse was observed in this analysis.

While comparison with previously published reports remains difficult, our results are promising. Indeed, in the literature, the PFS ranged from 29 to 80% and the OS from 41 to 80%; the toxicity seems also to be lower in our study because the aGVHD ranged from 21 to 33% and the NRM from 12-34% [10, 28, 30–35]. Many reasons can contribute to these differences: patients selection and inclusion criteria, GVHD prophylaxis and conditioning regimen heterogeneity. Regarding this last point, Wulf et al. reported on 80 advanced patients (only 15% in CR at allo), receiving allo-SCT from MRD (26%), MURD (63%) and mis-matched URD (11%), using a myeloablative conditioning regimen (fludarabine, busulfan, and cyclophosphamide). The 5-y OS was 38%, but the toxicity was extremely high (3 and 5-year NRM 32% and 46%, respectively) [36]. Finally, almost all studies reported only MDS and URD, and very few patients were allografted from haploidentical donors [18, 19].

Globally comparing RD to URD is also of interest, as part of a pragmatic approach to offer allo-HSCT to all patients in need of these treatments. Indeed, for underrepresented minorities in international registries, or in low- to middle income countries, as in the context of acute crises such as COVID-19, allo-HSCT from RD represents an attractive opportunity because of its lower cost [37] and relative easiness to organize. In our study, while OS and PFS were not statistically different, grade 2–4 acute GVHD and NRM were lower in the RD group, reinforcing this assumption. This may even open the door for further consideration in a wider population, but request should be prospectively addressed.

This study suffers from its retrospective nature and in particular from the evident patient selection, which can explain the outcomes observed. Furthermore, the sample size was limited, the period of inclusion was quite long with inherent heterogeneity regarding the treatment before transplantation, conditioning regimens, donor choice and supportive care.

However, this is a real-life selection of heavily pre-treated patients, achieving a complete or partial remission.

This study indicates that allo-SCT is highly effective in PTCL, with low NRM and low relapse rates. Results from transplantation from RD compare favorably with URD, but confirmation is awaited with more patients.

**Compliance with ethical standards**

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117:6756–67.

2. Simon A, Peoch M, Casassus P, Decominck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of randomized phase III trial GOLEAMS-LTP95. Br J Haematol. 2010;151:159–66.

3. D’Amore F, Relander T, Lauritzen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.

4. Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem cell transplantation as first line therapy in peripheral T cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.

5. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T cell lymphoma not otherwise specified and angioimmunoblastic T cell lymphoma. Br J Haematol. 2017;176:750–8.

6. Mak V, Hamm J, Chhanabhai M, SheinKier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.

7. Ellin F, Landstrom J, Jekerman M, Relander T. Real world data on prognostic factors and treatment in peripheral T cell lymphomas: a study the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.

8. Broccoli A, Argnani L, Zinzani PL. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev. 2017;60:120–9.

9. Le Guillou S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohiy M, et al. Graft –versus lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie cellulaire. J Clin Oncol. 2008;26:2264–71.

10. Jacobsen ED, Kim HT, Cutler V, Ho VT, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22:1608–13.
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of… 889

11. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520–6.

12. Kim SM, Yoon SS, Suzuki R, Matsuno Y, Hy HG, Yhoshida T, et al. Comparison of outcome between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma with central review of pathology. Leukemia. 2013;27:1394–440.

13. Lortat J, Chevallier P, Leucx C, Moreau A, Bossard C, Guillaume T, et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol. 2015;26:386–92.

14. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.

15. Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1279–87.

16. Martinez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35:3425–32.

17. Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transpl. 2017;52:683–8.

18. Kanate AS, Mussetti A, Khafan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–47.

19. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus hla-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34:3141–9.

20. Dietrich S, Finel H, Martinez C, Tischer J, Blaise D, Chevallier P, et al. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia. 2016;30:2086–9.

21. Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3:360–9.

22. Gauthier J, Castagna L, Garnier F, Guillaume T, Socié G, Maury S, et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transpl. 2017;52:689–96.

23. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic bone or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transpl. 2013;19:602–6.